Rheumatoid Arthritis Data Position Filgotinib Ahead Of Competition, But It's Playing Catch-Up
Executive Summary
Prospects rose for Galapagos and partner Gilead's JAK1 inhibitor with impressive Phase III FINCH 2 data in patients with moderate-to-severe rheumatoid arthritis.
You may also be interested in...
Mortality Signal For Pfizer's Xeljanz In Rheumatoid Arthritis Puts A Damper On JAK Class
Analyst speculates that risk of pulmonary embolism for a higher unapproved dose of Xeljanz in arthritis could trigger a label change for the same regimen in the drug's ulcerative colitis indication.
Galapagos Targets Liver Fibrosis With Evotec Deal
Belgium’s Galapagos adds another potential fibrosis drug to its growing pipeline of compounds in a therapeutic area that is also attracting attention from a number of other companies.
Keeping Track: US FDA Receives Submissions Galore As Year Ends
A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.